Suzhou zanrong pharma limited
Web28 ott 2024 · Originator Suzhou Zanrong Pharmaceutical Technology Class Antineoplastics; Small molecules Mechanism of Action Receptor protein-tyrosine kinase antagonists Orphan Drug Status No New Molecular Entity Yes Highest Development Phases Phase I Solid tumours Most Recent Events WebSUZHOU ZANRONG PHARMA LIMITED (Suzhou, CN) International Classes: A61K31/5025; A61K31/5377; C07D487/04. View Patent Images: Download PDF 20240047595 . Primary Examiner: CENTRAL, DOCKET ... The present invention is in no way limited to the methods and materials described.
Suzhou zanrong pharma limited
Did you know?
Web知识产权-苏州赞荣医药科技有限公司 ꁘ ꀐ 赞荣医药在2024年9月申请了第一个专利，拥有一批年轻的专利产权。 目前，我公司拥有与其首个项目相关的三项专利。 公司的知识产权 … Web10 ago 2024 · Zion Pharma Raises $20 Million in Series A+ Financing - vcbeat Zion Pharma Raises $20 Million in Series A+ Financing By Mailman Aug. 10th 2024 Share According to VCBeat, Suzhou Zanrong Pharmaceutical Technology Co., Ltd. ("Zion Pharma") announced the completion of a $20 million Series A+ financing.
Web18 set 2024 · Suzhou Zanrong Pharma Overview Update this profile Founded 2024 Status Private Latest Deal Type Series B Latest Deal Amount $40M Investors 5 General Information Contact Information Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Office Hong Kong Suzhou Zanrong Pharma Timeline … Web16 gen 2024 · The leading HER2 Positive Breast Cancer Companies Ambrx, Alteogen, Suzhou Zanrong Pharma Limited, AstraZeneca, Shanghai Henlius Biotech, …
WebSuzhou, April 14, 2024 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the first patient enrollment in Phase II clinical trial of its in-house developed first-in-class proteolysis targeting chimera … Web知识产权-苏州赞荣医药科技有限公司 ꁘ ꀐ 赞荣医药在2024年9月申请了第一个专利，拥有一批年轻的专利产权。 目前，我公司拥有与其首个项目相关的三项专利。 公司的知识产权战略如下: (1) 通过进一步申请晶体结构和药物剂型的专利，延长产品生命周期; (2) 申请专利，建立防御地位，防止竞争对手在赞荣医药的化学空间取得专利; (3) 在产品生命周期中申请 …
Web25 ott 2024 · Suzhou Zanrong Pharma Limited: ClinicalTrials.gov Identifier: NCT05593094 Other Study ID Numbers: ZN-A-1041-101-US : First Posted: October 25, 2024 Key …
Web11 apr 2024 · Complet Drotavérine HCL Marché Analyse des prévisions par (2024-2032): Sanofi, Medicover, RA Chem Pharma Limited, Synthokem Labs by RebeccaW Posted on 11 avril 2024 Marché mondial Drotavérine HCL comprend des informations détaillées sur la définition du produit, le type de produit, l’application et la tarification. physioausbildung speyerhttp://www.chinabiotoday.com/articles/zanrong-20-million-cancer tool to generate soap request from wsdlWeb10 lug 2024 · October 9, 2024 updated by: Suzhou Zanrong Pharma Limited A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN … physio aurichWeb16 gen 2024 · The leading HER2 Positive Breast Cancer Companies Ambrx, Alteogen, Suzhou Zanrong Pharma Limited, AstraZeneca, Shanghai Henlius Biotech, GeneQuantum Healthcare (Suzhou) Co., Ltd., ... tool to flare steelWeb22 mar 2024 · The leading HER2 Positive Breast Cancer Companies Ambrx, Alteogen, Suzhou Zanrong Pharma Limited, AstraZeneca, Shanghai Henlius Biotech, … tool to function analogy exampleWebBiotechnology Headquarters Regions Asia-Pacific (APAC) Founded Date 2024 Founders Ding Zhou, Ziqiang Cheng Operating Status Active Last Funding Type Series B Also … tool to generate json schema from json dataWebSuzhou Pharmaceutical Group Co. Ltd. manufactures and distributes pharmaceutical products. The Company produces antibiotics, estrogenic agents, nonsteroidal anti … tool to format drives